Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community

Multiple Sclerosis and Related Disorders

Volumn 17, Issue , 2017, Pages 116-122

  Eaneff, Stephanie ^a   Wang, Victor ^a   Hanger, Morgan ^a   Levy, Michael ^b   Mealy, Maureen A ^b   Brandt, Alexander U ^c   Eek, Daniel ^d   Ratchford, John N ^e   Nyberg, Fredrik ^d   Goodall, Jonathan ^f   Wicks, Paul ^a  

^a PATIENTSLIKEME INC   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ASTRAZENECA R AND D   (Sweden)

^e MEDIMMUNE   (United States)

^f ASTRAZENECA   (United Kingdom)

Author keywords

Devic's syndrome; Multiple sclerosis; Neuromyelitis optica; Patient Reported Outcomes; Quality of life

Indexed keywords

AZATHIOPRINE; BACLOFEN; DULOXETINE; GABAPENTIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; PREGABALIN; RITUXIMAB;

ADULT; AGE DISTRIBUTION; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY; ARTICLE; ATTITUDE TO ILLNESS; CHILD; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DISEASE SEVERITY; ENTEROPATHY; FATIGUE; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE RIGIDITY; MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; ONSET AGE; PAIN; PARKINSON DISEASE; PERSONAL EXPERIENCE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SPASTICITY; YOUNG ADULT; ADOLESCENT; DISABLED PERSON; INTERNET; PATHOPHYSIOLOGY; PSYCHOLOGY; SELF REPORT;

ADOLESCENT; ADULT; AGED; CHILD; DISABLED PERSONS; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SELF REPORT; YOUNG ADULT;

EID: 85024100055     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2017.07.014     Document Type: Article

References (29)

1. Blanc, F., Zephir, H., Lebrun, C., et al. Cognitive functions in neuromyelitis optica. Arch. Neurol. 65 (2008), 84–88.
2. Bove, R., Secor, E., Healy, B.C., et al. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One, 8, 2013, e59707.
3. Bradl, M., Kanamori, Y., Nakashima, I., et al. Pain in neuromyelitis optica – prevalence, pathogenesis and therapy. Nat. Rev. Neurol. 10 (2014), 529–536.
4. Chanson, J.B., Zephir, H., Collongues, N., et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur. J. Neurol. 18 (2011), 836–841.
5. Chavarro, V., Mealy, M., Pache, F., et al. Pain, fatigue and depression in patients with neuromyelitis optica spectrum disorder in Europe and USA. Neurology, 86(P6), 2016, 155.
6. Chen, H., Zhang, Y., Shi, Z., et al. The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin. Neuropharmacol. 39 (2016), 81–87.
7. Cree, B.A., Lamb, S., Morgan, K., Chen, A., Waubant, E., Genain, C., An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64 (2005), 1270–1272.
8. Eichler, G.S., Cochin, E., Han, J., et al. Exploring concordance of patient-reported information on PatientsLikeMe and medical claims data at the patient level. J. Med. Internet Res., 18, 2016, e110.
9. Flanagan, E.P., Cabre, P., Weinshenker, B.G., et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann. Neurol. 79 (2016), 775–783.
10. Huh, S.Y., Kim, S.H., Hyun, J.W., et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol. 71 (2014), 1372–1378.
11. Jacob, A., Matiello, M., Weinshenker, B.G., et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol. 66 (2009), 1128–1133.
12. Julian, L.J., Vella, L., Vollmer, T., Hadjimichael, O., Mohr, D.C., Employment in multiple sclerosis. Exiting and re-entering the work force. J. Neurol. 255 (2008), 1354–1360.
13. Lennon, V.A., Wingerchuk, D.M., Kryzer, T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004), 2106–2112.
14. Mandler, R.N., Ahmed, W., Dencoff, J.E., Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51 (1998), 1219–1220.
15. Marrie, R.A., Gryba, C., The incidence and prevalence of neuromyelitis optica: a systematic review. Int. J. MS Care 15 (2013), 113–118.
16. Mealy, M.A., Wingerchuk, D.M., Greenberg, B.M., Levy, M., Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch. Neurol. 69 (2012), 1176–1180.
17. Moore, P., Methley, A., Pollard, C., et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. J. Neurol. Sci. 360 (2016), 4–9.
18. Mutch, K., Methley, A., Moore, P., Jacob, A., Life on hold: the experience of living with neuromyelitis optica. Disabil. Rehabil. 36 (2014), 1100–1107.
19. Pandit, L., Asgari, N., Apiwattanakul, M., et al. Demographic and clinical features of neuromyelitis optica: a review. Mult. Scler. 21 (2015), 845–853.
20. Papadopoulos, M.C., Bennett, J.L., Verkman, A.S., Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat. Rev. Neurol. 10 (2014), 493–506.
21. Sellner, J., Boggild, M., Clanet, M., et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol. 17 (2010), 1019–1032.
22. Sharrack, B., Hughes, R.A., The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult. Scler. 5 (1999), 223–233.
23. Slawsky, K.A., Massagli, M.P., Wicks, P., A comparison of the patientslikeme quality of life questionnare (PLMQOL) with the RAND SF-36. Value Health, 14, 2011, A426.
24. Weinstock-Guttman, B., Ramanathan, M., Lincoff, N., et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch. Neurol. 63 (2006), 957–963.
25. Wicks, P., Massagli, M., Frost, J., et al. Sharing health data for better outcomes on PatientsLikeMe. J. Med. Internet Res., 12, 2010, e19.
26. Wicks, P., Vaughan, T.E., Massagli, M.P., The multiple sclerosis rating scale, revised (MSRS-R): development, refinement, and psychometric validation using an online community. Health Qual. Life Outcomes, 10, 2012, 70.
27. Wingerchuk, D.M., Lennon, V.A., Pittock, S.J., Lucchinetti, C.F., Weinshenker, B.G., Revised diagnostic criteria for neuromyelitis optica. Neurology 66 (2006), 1485–1489.
28. Wingerchuk, D.M., Lennon, V.A., Lucchinetti, C.F., Pittock, S.J., Weinshenker, B.G., The spectrum of neuromyelitis optica. Lancet Neurol. 6 (2007), 805–815.
29. Wingerchuk, D.M., Banwell, B., Bennett, J.L., et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85 (2015), 177–189.